Way beyond the rule of 5
The future of DMPK in a multimodality world
June 12th, 2019
Merck Research Laboratories
Morning Session I: Protein Biotherapeutics
Scientist, Pharmacokinetics & Drug Metabolism, Amgen
Presents: "In Vitro and In Vivo ADME of Biotherapeutic Proteins in Discovery and Development/Parallels to SM ADME"
Senior Principal Scientist, PPDM, Merck
Presents: "Integrated Fluorescent-Based Approach to Assess the In Vivo Fate of Experimental Biologics"
Head of DMPK US, Sanofi
Presents: "Biotherapeutics: Use of Modeling and Simulation Approaches for Decision Making"
Morning Session II: Cellular Therapy
Director, Analytical Design in Cell Therapies, Takeda Pharmaceuticals
Presents: "What is Needed to Support a CART Clinical Trial"
Head of Analytics, Cell Therapy, Takeda Pharmaceuticals
Presents: "Advancing Product Analytics for Cell Therapies"
Afternoon Session I: siRNA/ASO
Principal Scientist, Pharmacokinetics & Drug Metabolism, Amgen
Presents: " Transforming Traditional SM ADME Assays to Support the Translation of siRNA Pharmacology from the Benchtop to the Clinic"
VP, Early Development, Alnylam Pharmaceuticals
Presents: "The Use of ADME Sciences to Advance RNA Interference Therapeutics"
Xiao Shelley Hu
Director, DMPK and Clinical Pharmacology, Wave Life Sciences
Presents: "Special ADME Considerations in ASO Development"
Afternoon Session II: Gene Therapy/CRISPR
VP, Biological Development, Editas Medicine
Presents: "Editas Experience from Discovery to IND Acceptance of the CRISPR Medicine Focusing on the Bioassay"
Submission deadline: June 3rd, 2019
Maximum Poster size: 3’W X 4’H
Please email your poster title and abstract to email@example.com by 5 PM, June 3rd, 2019
Continental Breakfast, Registration and Poster Set-Up will begin at 8:00 AM
Presentations will begin at 8:30 AM
'For further information, email: Sirimas.firstname.lastname@example.org'
Registration/Cancellation Deadline: 5PM June 5th, 2019
If you cannot attend this meeting, but wish to make a donation to NEDMDG - please use the following link: